Transparent Peptidehttps://transparrentpeptide.comDated GLP-1 and peptide evidence, pricing and regulation. Every figure carries the date it was read.en-usTue, 04 Aug 2026 09:00:00 +0000We have withdrawn a named medical reviewer credit from every page on this sitehttps://transparrentpeptide.com/news/reviewer-credit-withdrawn/https://transparrentpeptide.com/news/reviewer-credit-withdrawn/Tue, 04 Aug 2026 09:00:00 +0000EditorialThe credit appeared in 112 bylines and 24 structured-data blocks. Both were removed together, and the change is published rather than made silently.The approved oral semaglutide tablet is $149 at starter doses and $299 at maintenancehttps://transparrentpeptide.com/news/approved-oral-price-is-a-ladder/https://transparrentpeptide.com/news/approved-oral-price-is-a-ladder/Tue, 04 Aug 2026 09:00:00 +0000PricingThe manufacturer's own price guide sets two tiers. The $149 rate on the 4 mg dose ends 31 August 2026.Canada has approved generic semaglutide. The US wall holds to at least 2032https://transparrentpeptide.com/news/semaglutide-patent-expiry-canada/https://transparrentpeptide.com/news/semaglutide-patent-expiry-canada/Tue, 04 Aug 2026 09:00:00 +0000RegulatoryThe foundational patent expired 20 March 2026 in four markets and lapsed in Canada, which approved its first two generics in April and May.The GLP-1 Patent Cliff: Why a Generic Arrives in Canada Before the United Stateshttps://transparrentpeptide.com/research/glp1-patent-cliff-2026/https://transparrentpeptide.com/research/glp1-patent-cliff-2026/Tue, 04 Aug 2026 09:00:00 +0000ResearchSemaglutide's foundational patent expired 20 March 2026 in India, China, Brazil and South Africa and lapsed in Canada. US protection runs to at least 2032. The dates, market by market.Peptides, Ranked by Evidence: What Has a Phase 3 Trial and What Has a Forum Posthttps://transparrentpeptide.com/research/peptide-evidence-tiers-2026/https://transparrentpeptide.com/research/peptide-evidence-tiers-2026/Tue, 04 Aug 2026 09:00:00 +0000ResearchBPC-157, TB-500, ipamorelin, sermorelin, tesamorelin and the GLP-1s sit at wildly different evidence levels. A tiered map of what each actually has behind it.GLP-1 Cost by State in 2026: Medicaid Coverage, Mandates and What You Actually Payhttps://transparrentpeptide.com/research/glp1-cost-by-state-2026/https://transparrentpeptide.com/research/glp1-cost-by-state-2026/Tue, 04 Aug 2026 09:00:00 +0000ResearchMedicaid coverage of GLP-1s for obesity varies by state, and a state with no coverage changes the cheapest route entirely. Coverage type, cash routes and what to ask, state by state.Rybelsus, Ozempic and Wegovy: One Molecule, Three Products, Three Different Answershttps://transparrentpeptide.com/research/rybelsus-vs-wegovy-vs-ozempic-2026/https://transparrentpeptide.com/research/rybelsus-vs-wegovy-vs-ozempic-2026/Tue, 04 Aug 2026 09:00:00 +0000ResearchAll three contain semaglutide. They differ in approved indication, maximum dose, route and price — and those differences decide coverage more than the molecule does.How to Verify a GLP-1 Provider in Five Minutes, Using Only Primary Sourceshttps://transparrentpeptide.com/research/how-to-verify-a-glp1-provider-2026/https://transparrentpeptide.com/research/how-to-verify-a-glp1-provider-2026/Tue, 04 Aug 2026 09:00:00 +0000ResearchFive free public databases settle whether a telehealth provider and its pharmacy are what they say. The checks, in order, and what each one can and cannot tell you.BPC-157 is on the FDA's Category 2 bulks list. It is still widely soldhttps://transparrentpeptide.com/news/bpc-157-category-2-status/https://transparrentpeptide.com/news/bpc-157-category-2-status/Mon, 03 Aug 2026 09:00:00 +0000SafetyCategory 2 identifies substances raising significant safety risks, which may not be used in 503A compounding. BPC-157 has no human efficacy trials.Two-thirds of lost weight returned within a year of stopping, and that reframes every price comparisonhttps://transparrentpeptide.com/news/stopping-glp1-regain-data/https://transparrentpeptide.com/news/stopping-glp1-regain-data/Mon, 03 Aug 2026 09:00:00 +0000EvidenceThe STEP-1 extension and SURMOUNT-4 both report regain on withdrawal. If treatment is ongoing, annual maintenance cost is the figure that matters.What Happens When You Stop a GLP-1: The Withdrawal Data, Trial by Trialhttps://transparrentpeptide.com/research/what-happens-when-you-stop-glp1-2026/https://transparrentpeptide.com/research/what-happens-when-you-stop-glp1-2026/Mon, 03 Aug 2026 09:00:00 +0000ResearchSTEP-1 reported about two-thirds of lost weight returned within a year of stopping. SURMOUNT-4 reported regain on withdrawal against continued loss on treatment. The numbers, and what they mean.NovoCare Pharmacy Pricing in 2026: Every Dose, Every Condition, Every Expiry Datehttps://transparrentpeptide.com/research/novocare-pharmacy-pricing-2026/https://transparrentpeptide.com/research/novocare-pharmacy-pricing-2026/Mon, 03 Aug 2026 09:00:00 +0000ResearchThe manufacturer's direct self-pay channel, read from its own price guide: $149 to $499 depending on product and dose, with two rates that expire on stated dates.The Advertised Price Is Not the Price: Membership Fees, Dose Tiers and Prepay Trapshttps://transparrentpeptide.com/research/membership-fees-and-hidden-costs-2026/https://transparrentpeptide.com/research/membership-fees-and-hidden-costs-2026/Mon, 03 Aug 2026 09:00:00 +0000ResearchFour pricing structures separate an advertised monthly figure from what lands on your card. How each works, and the four questions that surface all of them.Five free databases settle whether a provider is what it says. All five need one thing firsthttps://transparrentpeptide.com/news/verify-a-provider-in-five-minutes/https://transparrentpeptide.com/news/verify-a-provider-in-five-minutes/Sun, 02 Aug 2026 09:00:00 +0000GuideState board registers, FDA warning letters, the 503B list and openFDA recalls are searchable by company name — so a provider that will not name its pharmacy has ended the conversation.Four pricing structures separate an advertised GLP-1 figure from what lands on your cardhttps://transparrentpeptide.com/news/advertised-price-is-not-the-price/https://transparrentpeptide.com/news/advertised-price-is-not-the-price/Sun, 02 Aug 2026 09:00:00 +0000PricingMembership fees outside the headline, dose tiers, introductory rates and prepay-only pricing. They stack, and all four are visible if you ask four questions.The Legal Status of Compounded GLP-1s in 2026: What Actually Changedhttps://transparrentpeptide.com/research/compounded-glp1-legal-status-2026/https://transparrentpeptide.com/research/compounded-glp1-legal-status-2026/Sun, 02 Aug 2026 09:00:00 +0000ResearchThe FDA declared the semaglutide shortage resolved in February 2025. That ended the mass-compounding pathway. What remains is 503A patient-specific compounding, and it requires a documented reason.Liraglutide Has Two FDA-Approved Generics. Here Is Why It Is Still Not the Obvious Choicehttps://transparrentpeptide.com/research/liraglutide-generics-2026/https://transparrentpeptide.com/research/liraglutide-generics-2026/Sun, 02 Aug 2026 09:00:00 +0000ResearchGeneric liraglutide referencing Victoza arrived in December 2024 and Saxenda in August 2025. It is the cheapest approved GLP-1 — and it produced 6.4% against semaglutide's 15.8% head to head.GLP-1s and Muscle Mass: What the Body-Composition Sub-Studies Actually Foundhttps://transparrentpeptide.com/research/glp1-muscle-mass-2026/https://transparrentpeptide.com/research/glp1-muscle-mass-2026/Sun, 02 Aug 2026 09:00:00 +0000ResearchA share of weight lost on any effective intervention is lean mass. What the imaging sub-studies reported, what they could not measure, and why no protocol is evidence-based yet.GLP-1s slow gastric emptying, and a standard pre-operative fast may not empty the stomachhttps://transparrentpeptide.com/news/tell-your-anesthetist/https://transparrentpeptide.com/news/tell-your-anesthetist/Sat, 01 Aug 2026 09:00:00 +0000SafetyAnaesthesia guidance exists because case reports described residual gastric contents after adequate fasting. It applies to compounded products too.GLP-1 Side Effects Week by Week: When Nausea Peaks and When It Resolveshttps://transparrentpeptide.com/research/glp1-side-effects-by-week-2026/https://transparrentpeptide.com/research/glp1-side-effects-by-week-2026/Sat, 01 Aug 2026 09:00:00 +0000ResearchGastrointestinal effects cluster at dose increases rather than spreading evenly. What the trials reported, when discontinuation happens, and what the label says about the titration schedule.Tesamorelin (Egrifta): The One Growth-Hormone Peptide With an Approved Indicationhttps://transparrentpeptide.com/research/tesamorelin-egrifta-evidence-2026/https://transparrentpeptide.com/research/tesamorelin-egrifta-evidence-2026/Sat, 01 Aug 2026 09:00:00 +0000ResearchApproved for HIV-associated lipodystrophy, not for general fat loss or anti-ageing. What the trials established, the labelled risks, and why it is not comparable to a GLP-1.GLP-1s and Surgery: The Fasting Guidance That Changed, and Why It Mattershttps://transparrentpeptide.com/research/glp1-surgery-anesthesia-2026/https://transparrentpeptide.com/research/glp1-surgery-anesthesia-2026/Sat, 01 Aug 2026 09:00:00 +0000ResearchDelayed gastric emptying means a standard pre-operative fast may not empty the stomach. What anaesthesia guidance says, and why it applies to compounded products too.Two approved generic GLP-1s exist, and both are liraglutidehttps://transparrentpeptide.com/news/liraglutide-generics-available/https://transparrentpeptide.com/news/liraglutide-generics-available/Fri, 31 Jul 2026 09:00:00 +0000PricingA generic referencing Victoza was approved in December 2024 and one referencing Saxenda in August 2025. It is the cheapest approved route and the least effective.Who Should Not Take a GLP-1: Contraindications, Cautions and the Boxed Warninghttps://transparrentpeptide.com/research/who-should-not-take-a-glp1-2026/https://transparrentpeptide.com/research/who-should-not-take-a-glp1-2026/Fri, 31 Jul 2026 09:00:00 +0000ResearchA boxed warning, absolute contraindications and several situations requiring caution. What the labelling states and what an online intake should be asking you.Tesamorelin is approved for one indication, and almost none of its marketing describes that populationhttps://transparrentpeptide.com/news/egrifta-approved-for-one-thing/https://transparrentpeptide.com/news/egrifta-approved-for-one-thing/Thu, 30 Jul 2026 09:00:00 +0000SafetyEgrifta is approved for excess visceral abdominal fat in HIV-associated lipodystrophy. Not general fat loss, body recomposition or anti-ageing.